Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule inhibitor primarily known as PP2. It is a potent and selective inhibitor of Src family tyrosine kinases (including Src, Lck, Fyn, and Yes), with additional activity against other kinases such as Abl and p38 MAP kinase. It is widely used in research to study signal transduction pathways involving these kinases but has not been approved for clinical use. The compound is considered experimental and has not advanced beyond preclinical or early-stage research phases. Its mechanism involves competitive inhibition at the ATP-binding site of target kinases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-tert-butyl-3-(4-chloro-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine.